198 related articles for article (PubMed ID: 25323803)
1. Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease.
Miyoshi J; Hisamatsu T; Matsuoka K; Naganuma M; Maruyama Y; Yoneno K; Mori K; Kiyohara H; Nanki K; Okamoto S; Yajima T; Iwao Y; Ogata H; Hibi T; Kanai T
Digestion; 2014; 90(2):130-6. PubMed ID: 25323803
[TBL] [Abstract][Full Text] [Related]
2. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
3. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of adalimumab in patients with Crohn's disease: the experience of a single Canadian tertiary care centre.
Teriaky A; Gregor J; Yan B; Ponich T; Chande N; Mosli M
Scand J Gastroenterol; 2014 Mar; 49(3):280-6. PubMed ID: 24329040
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
[TBL] [Abstract][Full Text] [Related]
6. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Adalimumab in Korean Patients with Crohn's Disease.
Sohn IW; Kim ST; Kim B; Lee HJ; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
Gut Liver; 2016 Mar; 10(2):255-61. PubMed ID: 26470766
[TBL] [Abstract][Full Text] [Related]
9. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
10. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
11. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE.
Löfberg R; Louis EV; Reinisch W; Robinson AM; Kron M; Camez A; Pollack PF
Inflamm Bowel Dis; 2012 Jan; 18(1):1-9. PubMed ID: 21351211
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab induces deep remission in patients with Crohn's disease.
Colombel JF; Rutgeerts PJ; Sandborn WJ; Yang M; Camez A; Pollack PF; Thakkar RB; Robinson AM; Chen N; Mulani PM; Chao J
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):414-22.e5. PubMed ID: 23856361
[TBL] [Abstract][Full Text] [Related]
14. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
[TBL] [Abstract][Full Text] [Related]
16. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
Kiss LS; Szamosi T; Molnar T; Miheller P; Lakatos L; Vincze A; Palatka K; Barta Z; Gasztonyi B; Salamon A; Horvath G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovasz BD; Vegh Z; Golovics PA; Szathmari M; Papp M; Lakatos PL;
Aliment Pharmacol Ther; 2011 Oct; 34(8):911-22. PubMed ID: 21883326
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
19. Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
Chiu YL; Rubin DT; Vermeire S; Louis E; Robinson AM; Lomax KG; Pollack PF; Paulson SK
Inflamm Bowel Dis; 2013 May; 19(6):1112-22. PubMed ID: 23584130
[TBL] [Abstract][Full Text] [Related]
20. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
Schreiber S; Reinisch W; Colombel JF; Sandborn WJ; Hommes DW; Robinson AM; Huang B; Lomax KG; Pollack PF
J Crohns Colitis; 2013 Apr; 7(3):213-21. PubMed ID: 22704916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]